(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
She just became the first wheelchair user to travel to space - 2She was the ultimate '90s fitness influencer. Now she's delivering Uber Eats — and rebuilding her life.
- 35 Advancement Developments in Biotechnology
- 4The Most Paramount Crossroads in Olympic History
- 5Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- Figure out How to Get a good deal on Your Rooftop Substitution Venture
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- The 10 Most Noteworthy Games in History
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
